Tempus AI (NASDAQ:TEM) Price Target Lowered to $90.00 at BTIG Research

Tempus AI (NASDAQ:TEM) had its price objective lowered by analysts at BTIG Research from $105.00 to $90.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. BTIG Research’s price target points to a potential upside of 55.31% from the stock’s current price.

Several other equities analysts have also recently weighed in on the company. Mizuho began coverage on Tempus AI in a research note on Thursday, February 19th. They set an “outperform” rating and a $100.00 target price on the stock. HC Wainwright lowered their price objective on shares of Tempus AI from $98.00 to $89.00 and set a “buy” rating on the stock in a research report on Friday, November 7th. Needham & Company LLC upped their target price on Tempus AI from $70.00 to $100.00 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. Morgan Stanley lifted their price target on Tempus AI from $80.00 to $85.00 and gave the company an “overweight” rating in a report on Monday, December 1st. Finally, Robert W. Baird began coverage on Tempus AI in a report on Tuesday, February 17th. They issued an “outperform” rating and a $59.00 price objective on the stock. Eight analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $84.67.

Tempus AI Price Performance

Shares of NASDAQ:TEM opened at $57.95 on Wednesday. The company’s fifty day moving average is $61.92 and its two-hundred day moving average is $73.59. The company has a market cap of $10.31 billion, a P/E ratio of -48.70 and a beta of 5.22. Tempus AI has a 12-month low of $36.22 and a 12-month high of $104.32. The company has a quick ratio of 3.12, a current ratio of 3.28 and a debt-to-equity ratio of 2.45.

Insider Buying and Selling

In other Tempus AI news, EVP Andrew Polovin sold 10,949 shares of the company’s stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $60.31, for a total transaction of $660,334.19. Following the sale, the executive vice president directly owned 126,918 shares of the company’s stock, valued at approximately $7,654,424.58. This represents a 7.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Ryan Fukushima sold 9,592 shares of the stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $59.05, for a total value of $566,407.60. Following the sale, the chief executive officer owned 694,354 shares in the company, valued at approximately $41,001,603.70. This trade represents a 1.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 596,035 shares of company stock worth $37,505,125 in the last three months. Company insiders own 26.27% of the company’s stock.

Institutional Trading of Tempus AI

Hedge funds and other institutional investors have recently modified their holdings of the company. GC Wealth Management RIA LLC bought a new stake in shares of Tempus AI in the fourth quarter worth $399,267,000. Vanguard Group Inc. lifted its position in Tempus AI by 22.1% during the 3rd quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock worth $762,032,000 after buying an additional 1,706,837 shares in the last quarter. Voloridge Investment Management LLC lifted its position in Tempus AI by 183.0% during the 3rd quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company’s stock worth $129,708,000 after buying an additional 1,039,176 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Tempus AI by 312.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,274,549 shares of the company’s stock worth $102,869,000 after buying an additional 965,730 shares during the last quarter. Finally, AQR Capital Management LLC bought a new position in shares of Tempus AI in the 2nd quarter valued at about $54,020,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Trending Headlines about Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Morgan Stanley reaffirmed a Buy (Overweight) rating and kept an $85 price target, citing diversified growth, emerging profitability and a valuation discount versus peers. Analyst Note
• Positive Sentiment: Management set FY2026 revenue guidance around $1.59–$1.60 billion (~25% growth), driven by accelerating diagnostics and data businesses — a clear growth runway that underpins revenue multiple expansion potential. Guidance Article
• Positive Sentiment: Tempus reported strong Q4 revenue (up ~83% YoY in some company disclosures; consensus-beating quarter ~ $367M reported) and highlighted positive adjusted EBITDA, showing improving unit economics as scale builds. Press Release / Slides
• Positive Sentiment: Product and partnership cadence: launched HRD‑RNA algorithm for HRD detection and added lung‑cancer screening (Median Technologies partnership), expanding diagnostic addressable market and cross‑sell into imaging. Product/Partnership
• Neutral Sentiment: Full Q4 earnings call transcript and slide deck are available for details on unit economics, customer cadence, and backlog — useful for modeling margin and cash‑flow inflection timing. Earnings Transcript
• Negative Sentiment: Market reaction was mixed: some outlets note the stock pulled back after the print despite the revenue beat — investors flagged a muted/tempered outlook and execution risks around scaling operations and reimbursement dynamics. Market Reaction
• Negative Sentiment: EPS was still negative (reported loss per share in the quarter); some outlets flagged a mixed beat/miss signal on EPS versus different consensus reads — underlines ongoing path to consistent GAAP profitability. EPS Detail

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.